contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bbs-bioactive-bone-substitutes-plc-conversion-of-convertible-notes-pursuant-to-financing-arrangement-between-bbs-and-riverfort-global-opportunities-pcc-ltd-8

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

BBS-Bioactive Bone Substitutes is a medical technology company. The company designs, develops and constructs biological implants for patients with bone defects and healing problems. The company's solutions are resold under the Artebone brand and are based on tricalcium phosphate (TCP) and bone protein, which stimulates the bone healing process. The company was founded in 2003 and is headquartered in Oulu.

BBS-Bioactive Bone Substitutes

BBS-Bioactive Bone Substitutes Plc | Company Release | July 22, 2024 at 09:30:00 EESTBBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between...

<div class="mfn-header mfn-header-finland"><p>BBS-Bioactive Bone Substitutes Plc | Company Release | July 22, 2024 at 09:30:00 EEST</p></div><div class="mfn-preamble"><p><strong>BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd</strong></p></div><div class="mfn-body"><p>BBS-Bioactive Bone Substitutes Plc ("BBS") has received on July 19, 2024 requests from Riverfort Global Opportunities PCC Ltd ("Riverfort") to convert a proportion of EUR 50,000 of the convertible notes into Company shares at a conversion price of EUR 0.28521 per share. The conversion shall be executed by transferring a total of 175,309 treasury shares to Riverfort.</p><p>The Conversion price according to the terms and conditions is “90% of the lowest volume weighted average price of a trading day during ten trading days before the applicable subscription notice“.</p><p>After the transfers, the Company will hold a total of 276,838 treasury shares in its possession.</p></div><div class="mfn-footer mfn-contacts mfn-68bef424ac99"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Juliusz Rakowski, CEO<br>+358 50 448 5132<br><a rel="noopener" href="mailto:juliusz.rakowski@bbs-artebone.fi">juliusz.rakowski@bbs-artebone.fi</a></p></div><div class="mfn-footer mfn-1586e9e67a6a"><p><strong class="mfn-heading-1">Certified Advisor:</strong><br>Nordic Certified Adviser AB,<br>+46 70 551 67 29,<br><a rel="noopener" href="mailto:info@certifiedadviser.se">info@certifiedadviser.se</a></p></div><div class="mfn-footer mfn-67c8b2406f27"><p><strong class="mfn-heading-1">Distribution</strong><br>Nasdaq Helsinki<br><a rel="noopener" href="https://www.globenewswire.com/Tracker?data=dTX6KuwjXtC9yntip5ccELHgyMLbOC8p_qwAud8wR_OwuwTNIX6JB9T-9u2qDUKExAyUvAxRxfba9dWlnEvLjYC4hCeAo5EaIC_bkSh7hyM33b3gIm16ZVkdAzBgSsOw">https://www.bbs-artebone.fi/</a></p></div><div class="mfn-footer mfn-about mfn-838eb0731ac0"><p><strong class="mfn-heading-1">BBS in brief</strong><br><em>BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.</em><em><br></em><br><em>BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.</em><em><br></em><br><em>More information: </em><em><a rel="noopener" href="http://www.bbs-artebone.fi/">www.bbs-artebone.fi</a></em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/4e7d7482-51a9-44d2-aa00-f89d5e16b017/bbs-bioactive-bone-substitutes-plc-conversion-of-convertible-notes-pursuant-to-financing-arrangement-between-bbs-and-riverfort-global-opportunities-pcc-ltd.pdf" class="mfn-generated mfn-primary">BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd</a></p></div>

BBS-Bioactive Bone Substitutes Plc: Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort Global Opportunities PCC Ltd

Stay up to date with our newsletter